KAPA Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kairos Pharma, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.85 |
| Beta | 0 |
| 1 Month Change | -37.95% |
| 3 Month Change | -26.95% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| KAPA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -33.5% | -0.1% | -0.5% |
| 1Y | n/a | -6.4% | 23.2% |
Return vs Industry: Insufficient data to determine how KAPA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KAPA performed against the US Market.
Price Volatility
| KAPA volatility | |
|---|---|
| KAPA Average Weekly Movement | 21.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KAPA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KAPA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | John Yu | kairospharma.com |
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors.
Kairos Pharma, Ltd. Fundamentals Summary
| KAPA fundamental statistics | |
|---|---|
| Market cap | US$13.23m |
| Earnings (TTM) | -US$2.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs KAPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KAPA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.74m |
| Earnings | -US$2.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.3% |
How did KAPA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 15:49 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kairos Pharma, Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |